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Objective: To identify predictors of residual beta-cell function and
glycemic control during the first 12 months after the diagnosis of type 1
diabetes (T1D).
Subjects and Methods: Clinical information and blood samples were
collected from 275 children. HbA1c, antibodies, HLA typing and mixed
meal-stimulated C-peptide levels 1, 6, and 12 months after diagnosis were
analyzed centrally.
Results: Mean age at diagnosis was 9.1 yr. DKA with standard
bicarbonate <15 mmol/L was associated with significantly poorer residual
beta-cell function 1 (p = 0.004) and 12 months (p = 0.0003) after diagnosis.
At 12 months, the decline in stimulated C-peptide levels compared with the
levels at 1 month was 69% in the youngest age group and 50% in patients 10
yr and above (p < 0.001). Stimulated C-peptide at 12 months was predicted
by younger age (p < 0.02) and bicarbonate levels at diagnosis (p = 0.005),
and by stimulated C-peptide (p < 0.0001), postmeal blood glucose
(p = 0.0004), insulin antibodies (IA; p = 0.02) and glutamic acid
decarboxylase antibodies (GADA; p = 0.0004) at 1 month. HbA1c at
12 months was predicted by HbA1c at diagnosis (p < 0.0001), GADA at
1 month (p = 0.01), and non-white Caucasian ethnicity (p = 0.002).
Conclusions: Younger age, ketoacidosis at diagnosis, and IA and GADA
1 month after diagnosis were the strongest explanatory factors for residual
beta-cell function at 12 months. Glycemic control at 12 months was
influenced predominantly by ethnicity, HbA1c at diagnosis, and GADA at
1 month.
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Predictors of beta-cell function in new onset T1D
Introduction
Type 1 diabetes (T1D) is the end result of immune-
mediated beta-cell destruction. T-cells (autoreactive
CD8+ T effector cells and CD4+ T regulatory cells)
together with dendritic cells play a major pathogenic
role in islet cell infiltration and destruction that together
with cytokines/chemokines (IL-10, IL-1, IFNγ,TNFα)
are the constituents of the autoimmune processes (1). It
is generally accepted that at the time of T1D diagnosis,
an individual has lost most (60–80%) of the beta-
cell function but as many as 10–20% are still capable
of insulin production. Many children and adolescents
with newly diagnosed T1D experience a transient
remission period (’honeymoon’) starting shortly after
insulin treatment is initiated when the requirement for
exogenous insulin treatment declines (partial remission)
or even becomes non-existent (2, 3). It is reasonable to
consider that the partial remission phase is a period
of relative beta-cell recovery. The pathogenesis of this
has been the subject of discussion (4) but is likely to
be a combination of factors such as an amelioration
of glucose toxicity (5), a reduction in the immune
inflammatory conditions in the islets (insulitis) (6),
improvement of peripheral insulin sensitivity (7), or
even a still regenerating beta-cell mass (8). The
duration of the remission period depends at least partly
on the recovery of the beta-cell function, which may
be assessed by measurement of stimulated C-peptide
secretion (9, 10).
At diagnosis, pediatric patients with T1D present
with varying degrees of metabolic derangement. The
rate and severity of diabetic ketoacidosis (DKA) at
diagnosis vary considerably between countries and
regions (11, 12). Ketoacidosis at diagnosis has been
related in some studies to lower C-peptide values, higher
insulin requirements, and higher HbA1c values during
the first 2 yr of diabetes (13) but not in others (14).
Other factors affecting the remission phase have
been discussed and there remains some controversy
regarding the impact of various factors influencing
C-peptide secretion (4, 15).
This prospective study was initiated by the Hvidoere
Study Group on Childhood Diabetes (HSG), a
multinational collaboration of pediatric diabetes
centers, to describe the demography, patterns of clinical
and laboratory characteristics at diagnosis and to
explore the metabolic disturbance, genetic background,
and immune activity as predictors of residual beta-cell
function and glycemic control.
Material and methods
Subjects
The Hvidoere Remission Phase Study is a prospective,
long-term observational study conducted in 18 centers
representing 15 countries in Europe and Japan. Two
hundred and seventy-five children aged less than 16
yr with newly diagnosed diabetes presenting to the
pediatric departments of the participating centers
between August 1999 and December 2000 were
included in the study.
Exclusion criteria were suspected non-T1D [maturity-
onset diabetes of the young (MODY), secondary dia-
betes, etc.], and patients initially treated outside of the
centers for more than 5 d. Patients were diagnosed
according to the World Health Organization criteria.
A number of eligible patients or parents declined to
participate. The study was performed according to
the criteria of the Helsinki II Declaration and was
approved by the local ethics committee in each center.
All the patients and their parents or guardians gave
informed consent.
Clinical descriptives on each patient were collected
at the first hospital visit, including date of birth,
gender, duration of symptoms, height, and weight.
Detailed hospital admission data, metabolic status
(blood glucose, pH, standard bicarbonate, and urinary
ketones were determined locally by quality controlled
standard laboratory methods), and insulin therapy were
recorded. Blood samples for centralized measurement
of HbA1c, genetics, immunology, and stimulated
C-peptide were collected prospectively.
Ketoacidosis was defined by a standard bicarbonate
value ≤15 mmol or – if no standard bicarbonate was
available – by a pH-value ≤7.3. Mild DKA: standard
bicarbonate >15 and ≤22 mmol/L or pH >7.3. No
DKA: standard bicarbonate >22 mmol/L or pH > 7.4.
Insulin
Insulin regimens were recorded 1, 3, 6, 9, and 12 months
after diagnosis. After 12 months 52.9% of the children
were on twice insulin daily, 25% on three times and
18.5% on four or more injections. Only a few children
(3.3%) received one insulin injection daily. A premixed
form of insulin was used in 72.3% of the children
on twice daily insulin. Only three children used an
insulin infusion pump while 13% were treated with a
rapid acting insulin analogue. Mean daily insulin dose:
0.72 ± 0.28 U/kg (mean ± SD).
HbA1c
Capillary samples for HbA1c analysis were collected
at diagnosis and after 1, 3, 6, 9, and 12 months at
each center and mailed to the Steno Diabetes Centre
(Denmark) using the Bio-Rad HbA1c sample prepa-
ration kit (Bio-Rad Laboratories, Munich, Germany)
as previously described (16). HbA1c analysis was per-
formed by automatic high-pressure liquid chromatog-
raphy with the same calibrator lots as used in The
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Diabetes Control and Complications Trial (DCCT)
to facilitate comparisons. Normal range for the Steno
method was 4.4–6.3% (about 0.3% higher than the
DCCT method).
C-peptide
After 1, 6, and 12 months of diabetes, a liquid
meal challenge was utilized to stimulate endogenous
C-peptide release. There were 133 girls and 129 boys,
who contributed with at least one measurement (95%
of total). The test was in the morning after fasting for
at least 8 h, the morning insulin dose being omitted.
Boost (formerly Sustacal; Mead Johnson, Evansville,
IN, USA) was ingested in less than 10 min given at a
dose of 6 mL/kg (max: 360 mL). In agreement with the
DCCT protocol, capillary glucose was measured at time
0 and venous C-peptide and postmeal blood glucose at
90 min after ingestion of the liquid meal (15).
Serum samples were labeled and frozen at –20◦C
until shipment on dry ice to Steno Diabetes Center
for the determination of C-peptide. Samples were
thawed only once for the C-peptide assay. Serum
C-peptide was analyzed by a fluoroimmunometric
assay (AutoDELFIA™ C-peptide, PerkinElmer Life
and Analytical Sciences Inc., Turku, Finland). The
sensitivity was below 1 pmol/L, intra-assay coefficient
of variation below 6% at 20 pmol/L, and recovery of
standard, added to plasma before extraction, about
100% when corrected for losses inherent in the plasma
extraction procedure.
HLA
Typing of the HLA class II DRB1 locus was performed
by direct sequencing of exon 2 of DRB1 according to
the Immuno Histocompatibility Working Group (17).
DR 03/04 and DR 04/04 were defined as high-risk
genotypes (n = 97), while DR 03/03 and DR 04/08 were
considered to convey moderate risk (n= 31). All other
genotypes were classified as low risk (n = 130).
Antibody Measurements at 1, 6, and 12 months
Islet cell antibodies. Islet cell antibodies (ICA) of the
IgG class were detected by indirect immunofluorescence
using commercial Primate Pancreas slides from INOVA
Diagnostics, Inc. (San Diego, CA, USA). All initially
ICA-positive samples are re-tested to confirm anti-
body positivity. The sera were screened at a dilution of
1:2 and FITC-labeled anti-human IgG (Dako, Copen-
hagen, Denmark) was used as conjugate and grouped
as negative 0–0.5 U (Department of Autoimmunology,
Statens Serum Institut, Copenhagen, Denmark).
GAD antibodies. Glutamic acid decarboxylase antibod-
ies (GADA). Antibodies to the 65 kD isoform of
GAD were quantified by a direct radioimmunoas-
say (Diamyd Anti-GAD-65 RIA; Diamyd Diagnostics,
Stockholm, Sweden) according to the protocol pro-
vided by the manufacturer. Sera were run in duplicate,
and the results were read on a gamma counter (Wizard
1470; Wallac/PerkinElmer, Turku, Finland) and calcu-
lated from a standard curve. The cut-off limit was 10
units/mL and the intra- and interassay coefficients of
variation were 2.4 and 3.6%, respectively (Department
of Autoimmunology, Statens Serum Institut, Copen-
hagen, Denmark).
IA-2 antibodies. Antibodies to the protein tyrosine
phosphatase related IA-2 molecule were analyzed with
a radiobinding assay as previously described (18). The
results were expressed as relative units (RU) based
on a standard curve run on each plate using an
automated calculation program (multicalc; Wallac,
Turku, Finland). The limit for IA-2A positivity (≥ 0.77
RU) was set at the 99th percentile in 374 non-diabetic
children and adolescents. The interassay coefficient
of variation was <12%. This assay had a disease
sensitivity of 72% and a specificity of 100% based
on the 2005 Diabetes Autoantibody Standardization
Program (DASP) workshop.
Insulin antibodies. Insulin antibodies (IA) were measured
by a radioligand assay in a microplate format using
a modification of the method described by Williams
et al. (19). The cut-off limit for positivity is 1.56 RU
representing the 99th percentile in a group of 371 non-
diabetic subjects. The disease sensitivity of the assay
was 44% and the disease specificity 98% in the Centers
for Disease Control and Prevention (CDC)-sponsored
DASP Workshop in 2005.
Statistical analysis
Data were transmitted anonymously by the centers;
patients were identified by center number and patient
code. Data are presented as mean and range for non-
normally distributed parameters and mean ± standard
deviation for normally distributed parameters. Data
were evaluated using cross-tabulation and chi-squared
statistics and one-way analysis of variance. A p-value
of <0.05 is considered significant. Data for the course
over time was analyzed as a repeated measurements
model. C-peptide was studied on logarithmic scale with
an arbitrary effect of duration, and with an interaction
with age. Prediction of C-peptide (logarithmic scale)
and HbA1c at 12 months was done by multiple
regression analysis including covariates for age groups
(0–4.9, 5–9.9, 10+yr), gender, standard bicarbonate at
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onset, initial blood glucose, BMI, HbA1c, postmeal
blood glucose and C-peptide (1 month), presence of
ICA, IA, IA-2A, and GADA (four variables, all
evaluated at 1 month). The insignificant variables were
excluded in a backward stepwise approach.
The influence of HLA risk groups on residual beta-
cell function and HbA1c was investigated by regression
analysis with HbA1c and the logarithm of stimulated
C-peptide as dependent variables accounting for
gender, age, 1, 6, and 12 months after diagnosis. The
relationship between autoantibodies and HLA risk
groups were analyzed by a Wilcoxon test. The analyses
were performed using sas version 9.1 (SAS Institute
Inc., Cary, NC, USA).
Results
Demographic and clinical characteristics
at diagnosis
Data were obtained from 275 patients (144 females).
Mean age at diagnosis was 9.1 yr (range 0.2–16.8 yr)
and 84% were white Caucasian. Clinical information
including anthropometric data, pubertal status, ethnic
affiliation, prediagnosis symptoms, and metabolic
status at diagnosis are summarized in Table 1. The
gender ratio did not differ among the three age groups
0–4.9 yr, 5–9.9 yr, and >10 yr (p = 0.15, χ2-test). The
number of participants in the three age groups was
48, 104, and 123, respectively. The mean duration of
symptoms was 3.3 wk for polydipsia and 3.1 wk for
polyuria. The average reported weight loss (mean ±
SD) was 3.1 ± 3.4 kg (n = 221) or 8% of previous
weight. This compares with the mean weight gain
2.8 ± 2.4 kg from diagnosis to 1 month (n = 259). The
duration of symptoms was shorter and the relative
weight loss lower in patients with a younger age of
onset (Table 1).
There were 73 non-participants not included in the
analysis: 60 being unable or unwilling to participate and
13 suspected to have non-T1D. There was no significant
difference with respect to gender distribution, age,
anthropometric data, HbA1c at diagnosis, ethnic
distribution or family history of diabetes between
patients included and non-participants (data not
shown). The number of subjects enrolled per center
ranged from 4 to 34 and rate of participation 46–100%.
The proportions of subjects with DKA (bicarbonate
levels ≤15 mmol/L) in the three age groups were 28, 22,
and 19% (p = 0.46), respectively (Fig. 1). Blood glucose
at diagnosis was significantly higher (p < 0.001) in the
youngest age group than in the two older groups, the
means (SD) being 28.0 (12.4), 23.0 (8.8), and 24.0
(8.5) mmol/L, respectively. The mean HbA1c (SD)
value at diagnosis was 10.3 (1.6)% in the 0–4.9 yr
age group, which was significantly lower than in the
5–9.9 yr old group [11.0 (2.0)%] and in the ≥10 yr old
age group [11.7 (2.3)%] (Fig. 2).
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Fig. 1. The influence of standard bicarbonate at diagnosis on
stimulated C-peptide during 12 months of follow-up. DKA groups:
≤15 mmol/L (solid), 15–22 mmol/L (dashed), and >22 (dot-dashed)
mmol/L. Children without ketoacidosis at diagnosis (standard
bicarbonate above 22 mmol/L) had significantly higher stimulated
C-peptide at 1 (p = 0.004) and 12 months (p = 0.0003) after diagnosis
compared to those with standard bicarbonate below 15 mmol/L.
Table 1. Clinical and demographic data at onset by age groups
Age <5 yr 5 ≥ age <10 yr age ≥10 yr
Number (male/female) 19/29 57/47 55/68
Mean age (Range) (yr) 3.1 (0.21–4.9) 7.8 (5.1–9.9) 12.4 (10.0–16.8)
Mean height (Range) (cm) 99.6 (74–136) 129 (104–158) 155 (128–191)
Mean weight (Range) (kg) 15.0 (9.0–26.0) 25.9 (14–45) 43.1 (23–90)
Mean BMI (Range) (kg/m2) 15.2 (11.3–20.7) 15.4 (10.1–21.3) 17.9 (12.1–31.6)
Prepubertal (%) 48 (100) 101 (97.1) 47 (38.2)
Postmenarcheal (%) 0 0 25 (36.8)
White Caucasian (%) 41 (85.4) 89 (85.6) 101 (82.1)
Mean duration polyuria (wk) 2.5 (0–8) 2.5 (0–10) 4.0 (0–52)
Mean duration polydipsia (wk) 2.5 (0–8) 2.6 (0–10) 4.1 (0–52)
Mean weight loss (Range) (% of previous weight) 5.5 (0–25) 7.9 (0–29.6) 9.1 (0–31.8)
Mean HbA1c (SD) (%) 10.3 (1.6) 11.0 (2.0) 11.7 (2.3)
Range 7.6–15.3 6.3–15.3 7.3–17.4
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Fig. 2. HbA1c percentage during the 12 months follow-up. After
3 months duration HbA1c reaches the lowest level and subsequently
increases in all age groups. The HbA1c level in the very young
children are significantly lower at onset (p < 0.0001) and at 1 month
(p < 0.0002) compared with older age groups and very few of the
young children enter partial remission at 3 months. The 5–9.9 yr old
children have significantly lower HbA1c values at 9 (p < 0.04) and
12 months (p < 0.03) compared to the older children.
Disease progression during the first 12 months
after diagnosis
Residual beta-cell function as assessed by stimulated
C-peptide concentrations was related to the initial
standard bicarbonate concentration. Those with a
standard bicarbonate below 15 mmol/L had signifi-
cantly lower C-peptide levels 1 (p = 0.004, estimate
for log C-peptide –0.41 suggesting 34% lower resid-
ual beta-cell function) and 12 months after diagnosis
(p = 0.0003, estimate for log C-peptide –0.71 suggest-
ing 51% lower residual beta-cell function) compared
to those with standard bicarbonate above 22 mmol/L
(Fig. 1).
Overall mean HbA1c (SD) declined from 11.2 (2.1)%
at diagnosis to 9.0 (1.3)% at 1 month and reached a
nadir at approximately 3 months in all age groups [6.9
(1.1)%]. Subsequently, HbA1c increased to a level of
7.9 (1.5)% at 12 months (Fig. 2).
Throughout the study period the very young children
(<5 yr) had significantly poorer residual beta-cell
function with about half the stimulated C-peptide level
as in children 10 yr or older (p < 0.0001) (Fig. 3).
The youngest children had also shown a faster loss
of residual beta-cell function compared to the older
age groups during the first 12 months of disease.
The decline in beta-cell function for a child below
5 yr from 1 to 12 months was 69%; for a child 10
yr or older, the decrease was 50% (p < 0.001) for
the difference in decline. Furthermore, the youngest
children had significantly higher IA 1 month after
diagnosis (p = 0.04) compared to the older age groups.
After 1 month 47% of the patients tested positive for
ICA and this decreased to 34% at 12 months, while
the frequency of GADA remained relatively stable at
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Fig. 3. Effect of age and diabetes duration on residual beta-cell
function. Stimulated C-peptide level at 1 (p < 0.0001) and 12 months
(p = 0.02) after diagnosis was significantly greater in the older age
group than in the 5–9.9 yr while stimulated C-peptide at 6 (p < 0.005)
and 12 months (p = 0.0007) was significantly lower in the youngest
age group compared to the 5–9.9 yr. The difference between age
0–4.9 and 10–16 yr is significant at all time points (p < 0.001).
67 and 61% during the observation period as did IA-2
antibodies at 73 and 69%. By contrast, the proportion
of patients with IA increased from 69 to 98% during
the same time period. Those with the presence of IA
at 1 month required higher daily insulin dose at 9 (0.13
U/kg, p = 0.006) and 12 months (0.13 U/kg, p = 0.008)
(Fig. 4). Interestingly, IA at 6 and 12 months were not
associated with stimulated C-peptide at 12 months.
There was no significant relationship of HbA1c to IA
during the observation period.
Prediction of stimulated C-peptide and HbA1c
after 12 months of clinical disease
The best predictors at diagnosis for stimulated
C-peptide concentrations at 12 months were age group
(p = 0.009) (estimate for log C-peptide –0.43 for
0–4.9 yr suggesting 35% lower C-peptide; estimate
for ≥10 yr 0.16 suggesting 17% higher C-peptide)
and standard bicarbonate level (estimate 0.028/mmol/L
suggesting 2.8% higher C-peptide per 1 mmol/L
increase in bicarbonate, p = 0.005). The 1 month
measurements contributing were C-peptide (estimate
0.59, p < 0.0001), presence of IA (estimate –0.38,
suggesting 32% lower C-peptide, p = 0.02), GADA
(estimate –0.48, suggesting 39% lower C-peptide, p <
0.0004), and postmeal blood glucose (estimate –0.06,
suggesting 6% lower C-peptide by 1 mmol/L increase
p < 0.0004) (Fig. 4). BMI, HbA1c, or HLA risk groups
were not significantly related to stimulated C-peptide
levels at 12 months. The best predictors for HbA1c
at 12 months were HbA1c at diagnosis (estimate
0.23, p < 0.0001), GADA at 1 month (estimate 0.48%
higher HbA1c, p = 0.012), and non-white Caucasian
ethnicity (estimate 0.86% higher HbA1c, p = 0.002).
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Fig. 4. (A) Insulin antibody (IA) negative patients (31% of the total) and (B) glutamic acid decarboxylase antibody (GADA) negative patients
(33%) at 1 month had significantly better residual beta-cell function (IA, p = 0.003, GADA, p = 0.005) 12 months after diagnosis compared to
IA and GADA positive patients.
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Fig. 5. Stimulated C-peptide according to HLA risk. The C-peptide
level progressively decreased in all HLA risk groups in the first
12 months after diagnosis. However, there were tendencies to suggest
a higher stimulated C-peptide level for patients of low HLA risk, but
this was not statistically significant at any of the time points.
Age, gender, standard bicarbonate, BMI, initial blood
glucose at diagnosis and ICA, IA, GADA, IA-2A,
C-peptide, and postmeal blood glucose at 1 month had
no significant effect.
The influence of HLA risk groups on residual
beta-cell function, HbA1c and autoantibodies
There was no statistically significant association
between stimulated C-peptide and HLA risk groups
(low, moderate, and high risk) at 1 (p = 0.60), 6
(p = 0.29), and 12 (p = 0.15) months after diagnosis
(Fig. 5). In addition HLA risk groups were not
statistically significantly associated with HbA1c and
autoantibodies (ICA, IA, GADA, IA-2A) at any of the
time points (data not shown).
Discussion
This multicenter prospective study was designed to
investigate, in children and adolescents with T1D,
interacting factors which might influence the decline
of beta-cell function and glycemic control during the
first 12 months after diagnosis. The main findings at
diagnosis are that the youngest children have higher
BG, lower HbA1c, more severe ketoacidosis, and higher
levels of IA. This may represent a shorter but more
aggressive prediabetes phase corresponding to a rapid
and more extensive destruction of beta-cells, relatively
smaller beta-cell mass or less regenerative beta-cell
capacity, in the very young children (Figs 1–3). Several
studies have reported an association between greater
loss of beta-cell function and younger age (10, 13,
14, 20), and more severe ketoacidosis at onset (21).
The best predictors for stimulated C-peptide levels at
12 months are age and bicarbonate level at diagnosis,
and the presence of IA and GADA levels 1 month
after diagnosis, which seem to be associated with
a more rapid loss of residual beta-cell function.
There was no association with high-risk HLA status.
The best predictors of glycemic control (HbA1c)
at 12 months were HbA1c at diagnosis, non-white
Caucasian ethnicity, and presence of GADA at
1 month but not C-peptide levels. Most studies have
been either retrospective or with small numbers of
young people, but in one of the larger prospective
studies from a single center, younger age, male
gender, and initial ICA positivity made a significant
contribution to the variation in C-peptide levels and
in loss of beta-cell function (20). That study also
reported that shorter symptom duration at onset
and ketoacidosis significantly predicted the rate of
loss of C-peptide secretion but showed no significant
differences in glycated hemoglobin values between
patients who secreted C-peptide and those who did
not (22). We have not been able to find a correlation
between duration of symptoms prior to diagnosis
and subsequent beta-cell function, perhaps because
our study is multicenter based and the questionnaire
lacked sensitivity in this area. Moreover, we have
not found a predictive association between beta-cell
function and HbA1c and this is in agreement with
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other studies (10, 23). Our results show a relationship
between two immunological markers (GADA, IA)
and stimulated C-peptide concentration indicating that
patients with these antibodies have a more rapid
decline in residual beta-cell function (Fig. 4). Others
have shown a significant independent effect of GADA
with decreased C-peptide concentration at 6 months
after diagnosis (10, 24), and GADA negative patients
were more likely to exhibit a remission phase (10, 25).
Some studies have also indicated that ICA-negative
patients have higher C-peptide levels (14, 26) but that
neither IA nor metabolic state at onset affects C-peptide
secretion (14, 26).
In the prediabetic phase among family members at
high risk of developing diabetes it has been argued that
the measurement of cytoplasmic ICA’s remains a better
predictor of beta-cell destruction than GADA and IA-
2A (27). Although this is not necessarily applicable to
the decline in residual beta-cell function after diagnosis,
our data indicate that ICA does not predict the
decline in endogenous insulin secretion 12 months after
diagnosis, whereas GADA and IA do. Our finding of
IA in 69% of the patients 1 month after diagnosis is
not surprising, as they represent a mixture of insulin
autoantibodies and antibodies induced by exogenous
insulin. However, the finding that IA after 1 month
can predict the C-peptide level after 12 months but not
when measured at 6 and 12 months indicates that IA
at 1 month mainly consist of autoantibodies. At 6 and
12 months the antibodies are influenced by exogenous
insulin treatment. At diagnosis IA can be detected
in more than 50% of children (25) and IA levels
increase soon after the initiation of insulin therapy
but may remain relatively stable thereafter (26). Most
studies have not shown an association between IA
and C-peptide secretion (14, 26), although it has been
argued that the finding of immune positivity (ICA, IA,
etc.) indicates a wider level of autoimmunity to as yet
unidentified autoantigens which may be important in
the initiation and progression of beta-cell loss (28).
This same HSG cohort has been studied by Nielsen
et al. (29) who reported that the IA titers at 1 and
6 months were significantly lower in the INS VNTR
(IDDM2) class III/III and class I/III genotype groups
compared with the class I/I genotype. In addition
stimulated serum C-peptide concentrations were twice
as high among carriers of the class III/III genotype
as compared with class I/I and class I/III genotypes
implicating a direct connection in vivo between the INS
VNTR class III alleles, a reduced humoral immune
response to insulin, and preservation of beta-cell
function in recent onset T1D. This is consistent with our
finding that high IA levels 1 month after diagnosis is
associated with a more rapid decline in residual beta-cell
function. Our observation indicates that the type of
antibodies (such as IA and GADA) is a better predictor
of the endogenous insulin secretion at 12 months than
the number of positive antibodies.
Glycated hemoglobin is the important clinical
outcome measured during the remission phase, and
indeed when the remission phase is defined as
a low insulin dose, near normal glycemia with
minimal glycosuria, then glycated hemoglobin has
been observed to be similarly reduced (Fig. 2). Some
studies have found a significant inverse relationship
between C-peptide and HbA1c at onset (30), and at
6 and 12 months we observed a similar relationship,
whereas other studies have failed to find such an
association (10, 26). In another report based on this
HSG cohort we have explored the importance of the
inverse relationship between HbA1c, insulin dose, and
C-peptide to create a surrogate measure of stimulated
C-peptide which is convenient and easy to use in the
daily routine (31). In adults it has been shown that
prolonged secretion of C-peptide may contribute to
better metabolic control (32).
We found that HbA1c at 12 months was predicted
only by HbA1c at diagnosis and GADA titers at
1 month. It is of interest that there may already
be factors operating before diagnosis determining
glycemic control later in the first year, including
ethnicity. When comparisons have been made between
children with new onset T1D in different parts of
Europe, ethnic differences were suggested as a cause for
a more aggressive disease process (33). Furthermore a
study between Canada and Finland showed that the
Finish children at diagnosis had lower blood glucose
and HbA1c values and higher C-peptide levels (34).
These intriguing differences are the subject of further
investigation by our multinational study group.
In Finland with a higher prevalence of multiplex
families with T1D, evidence has been generated
that the rate of onset and severity of symptoms
of T1D is increased in patients who are Dw3/Dw4
heterozygotes (35) and that C-peptide secretion is
affected by certain high-risk HLA genotypes. Our
results do not show a statistically significant association
between the HLA status and the progression of the
disease as assessed by the C-peptide levels (Fig. 5),
and this is consistent with other studies (10, 22). It
suggests that HLA genotypes are predisposing to the
onset of the disease but the partial recovery of the
injured beta-cell depends on other factors, including
the cytokine attack (36), improvement of peripheral
insulin sensitivity (7), and a regenerating beta-cell
mass (8).
However, as suggested above with respect to the
INS VNTR genes, there are other biological markers
which may well influence the beta-cell function, the
immunological processes and the rate of beta-cell
destruction (36). Our results suggest that C-peptide
and HbA1c at 12 months are predicted by the same
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variables at diagnosis or 1 month later. This may
illustrate the different dimensions of the disease
severity. Other variables that seem important are age,
severity of DKA, and ethnic factors. Both IA and
GAD autoantibodies seem to influence the process,
suggesting that, if predictions of beta-cell decline or
potential responses to interventional treatment are
required, it will be of value to measure these early
in the course of the disease. In our study antibodies
were measured at the same time (1 month) as C-peptide
stimulation, which could not take place earlier for
ethical reasons. In future studies, it might be preferable
to measure these and other antibodies at the time of
diagnosis, as they have a high predictive value for the
future course of the disease.
Conclusions
The study shows that residual beta-cell function and
glycemic control after 1 yr of clinical disease can be
predicted by objective factors present at diagnosis or
soon after diagnosis such as age, degree of metabolic
decompensation, and humoral immune responses.
The HSG is continuing to explore more complex
mechanisms, which may influence the decline in beta-
cell function such as recently described genetic factors,
levels of cytochemical attack, other factors which
mediate kemokines from the innate immune system and
beta-cell growth factors like the incretin hormones.
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